CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct 12, 2023–
Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.